1. Enhanced anti-cancer efficacy of arginine deaminase expressed by tumor-seeking Salmonella Gallinarum.
- Author
-
Duysak T, Kim K, Yun M, Jeong JH, and Choy HE
- Subjects
- Animals, Mice, Argininosuccinate Synthase metabolism, Argininosuccinate Synthase genetics, Cell Line, Tumor, Arginine metabolism, Humans, Salmonella genetics, Mice, Inbred BALB C, Chloroquine pharmacology, Chloroquine therapeutic use, Female, Colorectal Neoplasms pathology, Colorectal Neoplasms drug therapy, Colorectal Neoplasms microbiology, Colorectal Neoplasms genetics, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, Hydrolases metabolism, Hydrolases genetics
- Abstract
Amino acid deprivation, particularly of nonessential amino acids that can be synthesized by normal cells but not by cancer cells with specific defects in the biosynthesis pathway, has emerged as a potential strategy in cancer therapeutics. In normal cells, arginine is synthesized from citrulline in two steps via two enzymes: argininosuccinate synthetase (ASS1) and argininosuccinate lyase. Several cancer cells exhibit arginine auxotrophy due to the loss or down-regulation of ASS1. These cells undergo starvation-induced cell death in the presence of arginine-degrading enzymes such as arginine deaminase (ADI). Thus, ADI has emerged as a potential therapeutic in cancer therapy. However, the use of ADI has two major disadvantages: ADI of bacterial origin is strongly antigenic in mammals, and ADI has a short circulation half-life (∼5 h). In this study, we engineered tumor-targeting Salmonella Gallinarum to express and secrete ADI and deployed this strain into mice implanted with ASS1-defective mouse colorectal cancer (CT26) through an intravenous route. A notable antitumor effect was observed, suggesting that the disadvantages were overcome as ADI was expressed constitutively by tumor-targeting bacteria. A combination with chloroquine, which inhibits the induction of autophagy, further enhanced the effect. Anti-cancer effect of Salmonella Gallinarum expressing an arginine deiminase (ADI) on arginine-dependent tumors in situ., Competing Interests: Competing interests The authors declare no competing interests. Institutional Review Board Statement The animal study protocol was approved by the Ethics Committee of Chonnam National University–Institutional Animal Use and Care Committee (CNU IACUC-H-2020-7)., (© 2024. The Author(s), under exclusive licence to Springer Nature Limited.)
- Published
- 2024
- Full Text
- View/download PDF